Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with sCRT in Stage IIIB/C-IV Non-Squamous NSCLC
NCT07085182Phase 2Recruiting
- Sponsor
- Zibo Municipal Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Zibo Municipal Hospital. Started Jan 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07085182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085182.